Prediction of , index 1782
Prospective Prediction
- Prediction Index
- 1782
- Prediction Date
- Commercial Prediction
- FAILURE (commercially insufficient clinical benefit in OS inferior to chemotherapy yet numerically superior to BL-B01D1)
- Technical Prediction
- partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS numerically superior to chemotherapy yet numerically inferior to BL-B01D1); partial FAILURE (statistically insignificant clinical benefit in tolerability inferior to chemotherapy yet numerically superior to BL-B01D1)
Readout of
Prediction Validation
- Readout Date
- Prediction To Readout
- 15 days in advance
- Readout Data Interpretation
- statistically significant improvement in PFS over the SoC chemotherapy (without disclosure of the specific data and p-value; indicating probably weak efficacy in PFS).
- Press Release
- Press Release (businesswire.com)
Prediction Result
- Prediction Accuracy
- Correct Prediction
- Clinical Benefit Conclusion
- statistically probably weakly significant (in PFS) and commercially TBD (OS data not mature)
- Prediction Classification
- True Negative (TN)
Readout of
Prediction Validation
- Readout Date
- Prediction To Readout
- 262 days in advance
- Readout Data Interpretation
- patritumab deruxtecan failed to achieve statistically significant clinical benefit in OS compared with the SoC chemotherapy; and achieved 5.8 months mPFS; slightly superior to 5.6 months mPFS achieved by the SoC chemotherapy (HR = 0.77; P=0.011) (see add'l link below); BLA voluntarily withdrawn
- Press Release
- Press Release (finance.yahoo.com)
- Additional Readout Data
- Add'l Clinical Benefit Comparison Data (ascopubs.org)
Prediction Result
- Prediction Accuracy
- Correct Prediction
- Clinical Benefit Conclusion
- statistically significant yet weak efficacy (PFS) and commercially insufficient (non-superior OS)
- Prediction Classification
- True Negative (TN)